The United States Food and Drug Administration has expanded the approved usage of RESTYLANE Injectable Gel (Medicis Aesthetics) to include lip augmentation. RESTYLANE was previously approved to treat moderate to severe facial wrinkles and nasolabial folds. Its new label will include an indication for submucosal implantation for lip augmentation in patients over the age of 21. In addition, the RESTYLANE package insert will be amended to include both the new indication and results from the clinical trials for lip augmentation.